The effect of antibiotic resistance on the outcome of three 1‐week triple therapies against Helicobacter pylori
- 1 May 1999
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 13 (5), 667-673
- https://doi.org/10.1046/j.1365-2036.1999.00508.x
Abstract
: Resistance of Helicobacter pylori to antibiotics may be a major reason for treatment failure. : To evaluate the effect of primary H. pylori resistance to antibiotics on the cure rates of three anti-H. pylori 1-week triple therapies. : One hundred and sixteen consecutive patients diagnosed H. pylori-positive by gastric histology, rapid urease test and culture were enrolled. Activity of tested antibiotics was determined by means of the E-test. Patients were treated for 7 days with: (i) pantoprazole 40 mg o.d. plus amoxycillin 1 g b.d. and metronidazole 250 mg q.d.s. (PAM); (ii) pantoprazole 40 mg o.d. plus clarithromycin 250 mg b.d. and metronidazole 250 mg q.d.s. (PCM); or (iii) pantoprazole 40 mg o.d. plus amoxycillin 1 g b.d. and clarithromycin 250 mg b.d. (PAC). Two months after completion of therapy, endoscopy and gastric biopsies were repeated. : Primary resistance rates to metronidazole, clarithromycin and amoxycillin were 17.2, 6.9 and 0%, respectively. Overall H. pylori cure rates expressed as intention-to-treat and per protocol analyses were, respectively, 79% and 86% with PAM, 82% and 89% with PCM, and 85% and 85% with PAC. Significantly lower cure rates were observed in metronidazole-resistant patients treated with PAM (56% vs. 96%, P = 0.01) or PCM (50% vs. 97%, P = 0.01). A trend towards lower H. pylori cure rates was observed in clarithromycin-resistant patients treated with PCM (67% vs. 91%, P = 0.74) or PAC (50% vs. 87%, P = 0.68). : Primary resistance to metronidazole influences the H. pylori cure rate of anti-H. pylori proton pump inhibitor-based triple therapies which include this antibiotic. A similar trend exists for primary clarithromycin resistance.Keywords
This publication has 29 references indexed in Scilit:
- Short‐term low‐dose pantoprazole‐based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patientsAlimentary Pharmacology & Therapeutics, 1998
- Pantoprazole, amoxycilin and metronidazole in Helicobacter pylori-positive duodenal ulcer patients: Effects on symptoms, ulcer healing and eradication ratesGastroenterology, 1998
- Short‐course therapy with amoxycillin–clarithromycin triple therapy for 10 days (ACT‐10) eradicates Helicobacter pylori and heals duodenal ulcerAlimentary Pharmacology & Therapeutics, 1997
- Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands.Emerging Infectious Diseases, 1997
- Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.Gut, 1997
- Resistance of Helicobacter pylori to antibioticsAlimentary Pharmacology & Therapeutics, 1997
- Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitroJournal of Antimicrobial Chemotherapy, 1996
- Diagnosis of InfectionGut, 1995
- Results of a multicentre European survey in 1991 of metronidazole resistance inHelicobacter pyloriEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992